Bayer HealthCare Selects Tripos to Provide Drug Discovery Software For Its Global Enterprise
Tripos, Inc. and Bayer HealthCare AG have announced an agreement to deploy Tripos’ proprietary discovery informatics software, SYBYL(R) and UNITY(R), globally across Bayer’s drug discovery and development organization. Under the terms of the agreement, Tripos will provide Bayer with license rights to SYBYL and UNITY for its sites in Germany and the United States that are focused on the discovery and development of new therapeutics. Financial terms of the agreement were not disclosed.
The SYBYL computational chemistry and molecular modeling system is the heart of Tripos’ discovery software offering, providing the fundamental components for research scientists to understand molecular structure and properties, with a special focus on the creation of new chemical entities. UNITY adds functionality to SYBYL with rapid, conformationally-flexible three-dimensional searching of chemical and biological databases.
“The seamless integration of cheminformatics, pharmacophore modeling and protein structure-based design tools offered by Tripos’ software products will help us focus our synthesis efforts on promising compounds,” said Dr. Hanno Wild, vice president for medicinal chemistry at Bayer HealthCare.
Dr. Alexander Hillisch, head of computational chemistry at Bayer HealthCare AG, added, “Tripos’ ability to offer a complete computational chemistry suite, including sophisticated high-throughput docking programs on the Linux platform, was a critical factor in our choice.”
“We are excited to welcome Bayer HealthCare to the list of customers that have embraced our core business strategy of providing one of the most integrated drug discovery offerings available,” said Dr. John P. McAlister, president and CEO of Tripos. “Our range of scientific expertise combined with our innovative technological capabilities enables us to provide the breadth of informatics products and services and discovery research offerings our customers need to accomplish their goals.”
About Bayer HealthCare AG
Bayer HealthCare AG, a subgroup of Bayer AG with sales of approximately 8.9 billion Euros in 2003, is one of the world’s leading, innovative companies in the health care and medical products industry. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diagnostics and Pharmaceuticals. 34,600 people are employed by Bayer HealthCare worldwide. Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease. Further information on Bayer HealthCare AG can be found at http://www.bayerhealthcare.com
About Tripos, Inc.
Tripos (Nasdaq:TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Tripos collaborates with clients to accelerate and improve the creation of life-enhancing products. Within Tripos’ Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos’ Discovery Research (DR) business, Tripos’ medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Headquartered in St. Louis, Mo., Tripos spans the world with global research operations and an international client base. Further information on Tripos can be found at http://www.tripos.com
This press release may contain certain statements that are forward-looking and involve risks and uncertainties. Words such as “expects,” “anticipates,” “projects,” “estimates,” “intends,” “plans,” “believes,” variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are based on current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. We have identified certain factors that could cause actual results to differ materially from the forward-looking statements in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and our Current Reports on Form 8-K. Except as otherwise required under federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.
